Volume 12, Number 12—December 2006
Research
Human Metapneumovirus in Turkey Poults
Table 1
Treatment group | Clinical sign score | Average score | |||||
---|---|---|---|---|---|---|---|
4 d (n = 18) | 5 d (n = 18) | 6 d (n = 16)† | 7 d (n = 16)† | 8 d (n = 14)‡ | 9 d (n = 14)‡ | ||
Noninfected control | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hMPV A1 | 2.0 | 2.0 | 2.0 | 2.0 | 1.0 | 0 | 1.5 |
hMPV A2 | 8.0 | 6.0 | 4.0 | 4.0 | 3.0 | 1.0 | 4.34 |
hMPV B1 | 1.0 | 1.0 | 4.0 | 7.0 | 3.0 | 0 | 2.66 |
hMPV B2 | 8.0 | 6.0 | 8.0 | 8.0 | 6.0 | 2.0 | 6.34 |
aMPV C | 14.0 | 15.0 | 15.5 | 16.5 | 13.5 | 10.5 | 14.17
*d, days postexposure; hMPV, human metapneumovirus genotypes A1, A2, B1, B2; aMPV C, avian metapneumovirus subtype C. |
*d, days postexposure; hMPV, human metapneumovirus genotypes A1, A2, B1, B2; aMPV C, avian metapneumovirus subtype C.
†For the group exposed to hMPV B2, n = 15 because of 1 death (cause unknown) on day 5 postexposure.
‡For the group exposed to hMPV B2, n = 13 because of 1 death (cause unknown) on day 5 postexposure.
Page created: October 04, 2011
Page updated: October 04, 2011
Page reviewed: October 04, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.